Literature DB >> 25625748

Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases.

Hossein Jadvar1, Susan G Groshen, David I Quinn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25625748     DOI： 10.1148/radiol.14141593

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  5 in total

Review 1.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

Review 2.  PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

3.  Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.

Authors:  Sonam Suman; Rahul V Parghane; Amit Joshi; Kumar Prabhash; Ganesh Bakshi; Sanjay Talole; Sharmila Banerjee; Sandip Basu
Journal:  Br J Radiol       Date:  2019-11-01       Impact factor: 3.039

4.  Case of prostate stromal tumour of uncertain malignant potential where positron emission tomography with 18F-fluorodeoxyglucose was useful for surgical planning.

Authors:  Issei Suzuki; Toshiki Kijima; Atsuko Owada; Takao Kamai
Journal:  BMJ Case Rep       Date:  2020-09-10

5.  The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.

Authors:  Matteo Bauckneht; Francesco Bertagna; Maria Isabella Donegani; Rexhep Durmo; Alberto Miceli; Vincenzo De Biasi; Riccardo Laudicella; Giuseppe Fornarini; Alfredo Berruti; Sergio Baldari; Annibale Versari; Raffaele Giubbini; Gianmario Sambuceti; Silvia Morbelli; Domenico Albano
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-19       Impact factor: 5.554
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.